In This Article:
-
Revenue: Record revenues of $180 million for the first six months of 2024.
-
Adjusted EBITDA: Over $29 million for the first six months of 2024.
-
Oncology and Hematologic Disease Revenue: Approximately $36 million, a growth of 28% compared to the same period last year.
-
Other Specialty Portfolio Revenue: $20.6 million, an increase of 22% compared to the same period last year.
-
Infectious Disease Portfolio Revenue: $37.8 million, a decrease of 17% compared to the same period last year.
-
Gross Margin: $45.3 million or 48% of revenues in Q2 2024, compared to $40.2 million or 45% in the same period last year.
-
Operating Expenses: Approximately $30.1 million, an increase of 12% compared to the same period last year.
-
Adjusted EBITDA for Q2 2024: $15.7 million, an increase of 10% compared to the same period last year.
-
Cash Flows: Cash outflows from operations of $1.1 million in Q2 2024.
-
Financial Guidance for 2024: Expected revenues between $355 million to $365 million; adjusted EBITDA expected to be approximately 16% of revenues.
Release Date: August 08, 2024
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
-
Knight Therapeutics Inc (KHTRF) reported record revenues of $180 million for the first six months of 2024, excluding hyperinflation.
-
The company's innovative product portfolio grew by 12%, driven by products like Lenvima, Akynzeo, Trelstar, and the launch of Minjuvi in Brazil.
-
Knight Therapeutics Inc (KHTRF) expanded its pipeline with the in-licensing of Journey PM, a novel formulation for ADHD, complementing its neurology portfolio.
-
The oncology and hematologic disease portfolio saw a revenue increase of 28% compared to the same period last year.
-
Knight Therapeutics Inc (KHTRF) increased its financial guidance for 2024 revenues to between $355 million and $365 million, up from the previous range of $335 million to $350 million.
Negative Points
-
The infectious disease portfolio experienced a revenue decrease of 17% compared to the same period last year, primarily due to timing of orders and decreased demand for certain products.
-
Operating expenses increased by 12% compared to the same period last year, driven by higher G&A costs and development expenses.
-
Cash outflows from operations were $1.1 million during Q2 2024, influenced by an increase in working capital.
-
The company faces challenges with hyperinflation in Argentina, making it difficult to predict financial outcomes accurately.
-
Knight Therapeutics Inc (KHTRF) anticipates potential lumpy quarters and swings in working capital due to inventory purchases.